Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-010902 Size: 5 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-002277 Act: 34 Size: 29 KB 网页链接
$Nabriva Therapeutics(NBRV)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0000947871-19-000987 Act: 34 Size: 86 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-19-075598 Act: 34 Size: 96 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001047469-19-006929 Act: 33 Size: 552 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-19-074693 Act: 34 Size: 354 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-19-074617 Act: 34 Size: 36 KB 网页链接
$Nabriva Therapeutics(NBRV)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0000947871-19-000896 Act: 34 Size: 88 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-19-010818 Act: 34 Size: 7 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001104659-19-062629 Act: 34 Size: 4 MB 网页链接